Please enable JavaScript to continue using this application.

Compare tickers

Valuation, margins, and growth side by side.

Compare $LGND vs $OGN | Chartloom

Compare

$LGND vs $OGN

Ligand Pharmaceuticals Inc · Organon & Co

LGND

Ligand Pharmaceuticals Inc

OGN

Organon & Co

Compare $LGND vs $OGN

Comparing Ligand Pharmaceuticals Inc and Organon & Co

LGNDLigand Pharmaceuticals Inc

OGNOrganon & Co

LGNDLigand Pharmaceuticals Inc

Market cap

$6.08B

P/E (TTM)

33.61x

Forward P/E (NTM)

28.81x

Forward P/S (NTM)

17.73x

Rev growth (TTM)

54.9%

YTD performance

59.7%

52W performance

70.8%

FCF yield

2.2%

OGNOrganon & Co

Market cap

$3.62B

P/E (TTM)

17.82x

Forward P/E (NTM)

3.84x

Forward P/S (NTM)

0.58x

Rev growth (TTM)

-2.5%

YTD performance

90.2%

52W performance

43.4%

FCF yield

12.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

LGND

OGN

Detailed metrics comparison

LGND

Ligand Pharmaceuticals Inc

OGN

Organon & Co

Market Cap

LGND$6.08B

OGN$3.62B

Enterprise Value

LGND$6.20B

OGN$11.04B

Price

LGND$303.53

OGN$13.77

P/E Ratio

LGND33.61x

OGN17.82x

P/S Ratio

LGND20.94x

OGN0.59x

EV/Sales

LGND21.35x

OGN1.80x

EV/EBITDA

LGND42.81x

OGN6.50x

P/B Ratio

LGND6.22x

OGN3.61x

P/FCF Ratio

LGND45.31x

OGN8.33x

EV/FCF

LGND46.20x

OGN25.43x

PEG Ratio

LGND1.33x

OGNN/A

Forward P/E (NTM)

LGND28.81x

OGN3.84x

Forward P/S (NTM)

LGND17.73x

OGN0.58x

Revenue (TTM)

LGND$291M

OGN$6.13B

Revenue Growth (YoY)

LGND54.9%

OGN-2.5%

Forward Rev Growth

LGND31.3%

OGN1.6%

Gross Margin (TTM)

LGND95.4%

OGN52.7%

Operating Margin (TTM)

LGND32.6%

OGN8.0%

EBITDA Margin (TTM)

LGND45.8%

OGN27.7%

Net Margin (TTM)

LGND67.9%

OGN3.4%

FCF Margin (TTM)

LGND46.2%

OGN7.1%

Net Income (TTM)

LGND$197M

OGN$209M

FCF (TTM)

LGND$134M

OGN$434M

EPS (TTM)

LGND$9.03

OGN$0.77

ROE (TTM)

LGND20.1%

OGN23.4%

ROA (TTM)

LGND11.7%

OGN1.6%

ROIC (TTM)

LGND12.3%

OGN2.2%

Cash

LGND$1.01B

OGN$1.13B

Debt

LGND$1.13B

OGN$8.55B

Net Cash/Debt

LGND$-120M

OGN$-7.42B

Current Ratio (TTM)

LGND31.18x

OGN1.95x

Quick Ratio (TTM)

LGND30.96x

OGN1.44x

Debt/Equity (TTM)

LGND1.16x

OGN8.50x

Debt/Assets (TTM)

LGND0.0%

OGN0.0%

Interest Coverage (TTM)

LGNDN/A

OGNN/A

Net Debt/EBITDA (TTM)

LGND0.00x

OGN0.00x

Beta

LGND1.23

OGN1.50

52W Performance

LGND70.8%

OGN43.4%

YTD Performance

LGND59.7%

OGN90.2%

% from 52W High

LGND-7.1%

OGN-0.7%

% from 52W Low

LGND72.6%

OGN142.0%

Asset Turnover (TTM)

LGND0.17x

OGN0.47x

FCF Yield (TTM)

LGND2.2%

OGN12.0%

Earnings Yield (TTM)

LGND3.2%

OGN5.8%

Dividend Yield (TTM)

LGNDN/A

OGN0.5%

Rule of 40

LGND101.1

OGN4.6

EV/GP/RG

LGND1.14

OGN2.99

Ticker research

View LGND research View OGN research

Metric	LGND Ligand Pharmaceuticals Inc	OGN Organon & Co
Market & Valuation
Market Cap	$6.08B	$3.62B
Enterprise Value	$6.20B	$11.04B
Price	$303.53	$13.77
P/E Ratio	33.61x	17.82x
P/S Ratio	20.94x	0.59x
EV/Sales	21.35x	1.80x
EV/EBITDA	42.81x	6.50x
P/B Ratio	6.22x	3.61x
P/FCF Ratio	45.31x	8.33x
EV/FCF	46.20x	25.43x
PEG Ratio	1.33x	N/A
Forward P/E (NTM)	28.81x	3.84x
Forward P/S (NTM)	17.73x	0.58x
Revenue & Growth
Revenue (TTM)	$291M	$6.13B
Revenue Growth (YoY)	54.9%	-2.5%
Forward Rev Growth	31.3%	1.6%
Profitability
Gross Margin (TTM)	95.4%	52.7%
Operating Margin (TTM)	32.6%	8.0%
EBITDA Margin (TTM)	45.8%	27.7%
Net Margin (TTM)	67.9%	3.4%
FCF Margin (TTM)	46.2%	7.1%
Net Income (TTM)	$197M	$209M
FCF (TTM)	$134M	$434M
EPS (TTM)	$9.03	$0.77
ROE (TTM)	20.1%	23.4%
ROA (TTM)	11.7%	1.6%
ROIC (TTM)	12.3%	2.2%
Financial Health
Cash	$1.01B	$1.13B
Debt	$1.13B	$8.55B
Net Cash/Debt	$-120M	$-7.42B
Current Ratio (TTM)	31.18x	1.95x
Quick Ratio (TTM)	30.96x	1.44x
Debt/Equity (TTM)	1.16x	8.50x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.23	1.50
52W Performance	70.8%	43.4%
YTD Performance	59.7%	90.2%
% from 52W High	-7.1%	-0.7%
% from 52W Low	72.6%	142.0%
Efficiency & Yields
Asset Turnover (TTM)	0.17x	0.47x
FCF Yield (TTM)	2.2%	12.0%
Earnings Yield (TTM)	3.2%	5.8%
Dividend Yield (TTM)	N/A	0.5%
Other
Rule of 40	101.1	4.6
EV/GP/RG	1.14	2.99
Ticker research	View LGND research	View OGN research

Valuation

P/E Ratio

OGN

17.82x

LGND

33.61x

P/S Ratio

OGN

0.59x

LGND

20.94x

EV/FCF

OGN

25.43x

LGND

46.20x

Growth & revenue

Revenue Growth TTM

LGND

54.9%

OGN

-2.5%

Forward Revenue Growth

LGND

31.3%

OGN

1.6%

Profitability & performance

Gross Margin

LGND

95.4%

OGN

52.7%

ROE

OGN

23.4%

LGND

20.1%

FCF Yield %

OGN

12.0%

LGND

2.2%

52-Week Performance

LGND

70.8%

OGN

43.4%

Detailed metrics comparison

LGND

Ligand Pharmaceuticals Inc

OGN

Organon & Co

Market Cap

LGND$6.08B

OGN$3.62B

Enterprise Value

LGND$6.20B

OGN$11.04B

Price

LGND$303.53

OGN$13.77

P/E Ratio

LGND33.61x

OGN17.82x

P/S Ratio

LGND20.94x

OGN0.59x

EV/Sales

LGND21.35x

OGN1.80x

EV/EBITDA

LGND42.81x

OGN6.50x

P/B Ratio

LGND6.22x

OGN3.61x

P/FCF Ratio

LGND45.31x

OGN8.33x

EV/FCF

LGND46.20x

OGN25.43x

PEG Ratio

LGND1.33x

OGNN/A

Forward P/E (NTM)

LGND28.81x

OGN3.84x

Forward P/S (NTM)

LGND17.73x

OGN0.58x

Revenue (TTM)

LGND$291M

OGN$6.13B

Revenue Growth (YoY)

LGND54.9%

OGN-2.5%

Forward Rev Growth

LGND31.3%

OGN1.6%

Gross Margin (TTM)

LGND95.4%

OGN52.7%

Operating Margin (TTM)

LGND32.6%

OGN8.0%

EBITDA Margin (TTM)

LGND45.8%

OGN27.7%

Net Margin (TTM)

LGND67.9%

OGN3.4%

FCF Margin (TTM)

LGND46.2%

OGN7.1%

Net Income (TTM)

LGND$197M

OGN$209M

FCF (TTM)

LGND$134M

OGN$434M

EPS (TTM)

LGND$9.03

OGN$0.77

ROE (TTM)

LGND20.1%

OGN23.4%

ROA (TTM)

LGND11.7%

OGN1.6%

ROIC (TTM)

LGND12.3%

OGN2.2%

Cash

LGND$1.01B

OGN$1.13B

Debt

LGND$1.13B

OGN$8.55B

Net Cash/Debt

LGND$-120M

OGN$-7.42B

Current Ratio (TTM)

LGND31.18x

OGN1.95x

Quick Ratio (TTM)

LGND30.96x

OGN1.44x

Debt/Equity (TTM)

LGND1.16x

OGN8.50x

Debt/Assets (TTM)

LGND0.0%

OGN0.0%

Interest Coverage (TTM)

LGNDN/A

OGNN/A

Net Debt/EBITDA (TTM)

LGND0.00x

OGN0.00x

Beta

LGND1.23

OGN1.50

52W Performance

LGND70.8%

OGN43.4%

YTD Performance

LGND59.7%

OGN90.2%

% from 52W High

LGND-7.1%

OGN-0.7%

% from 52W Low

LGND72.6%

OGN142.0%

Asset Turnover (TTM)

LGND0.17x

OGN0.47x

FCF Yield (TTM)

LGND2.2%

OGN12.0%

Earnings Yield (TTM)

LGND3.2%

OGN5.8%

Dividend Yield (TTM)

LGNDN/A

OGN0.5%

Rule of 40

LGND101.1

OGN4.6

EV/GP/RG

LGND1.14

OGN2.99

Ticker research

View LGND research View OGN research

Metric	LGND Ligand Pharmaceuticals Inc	OGN Organon & Co
Market & Valuation
Market Cap	$6.08B	$3.62B
Enterprise Value	$6.20B	$11.04B
Price	$303.53	$13.77
P/E Ratio	33.61x	17.82x
P/S Ratio	20.94x	0.59x
EV/Sales	21.35x	1.80x
EV/EBITDA	42.81x	6.50x
P/B Ratio	6.22x	3.61x
P/FCF Ratio	45.31x	8.33x
EV/FCF	46.20x	25.43x
PEG Ratio	1.33x	N/A
Forward P/E (NTM)	28.81x	3.84x
Forward P/S (NTM)	17.73x	0.58x
Revenue & Growth
Revenue (TTM)	$291M	$6.13B
Revenue Growth (YoY)	54.9%	-2.5%
Forward Rev Growth	31.3%	1.6%
Profitability
Gross Margin (TTM)	95.4%	52.7%
Operating Margin (TTM)	32.6%	8.0%
EBITDA Margin (TTM)	45.8%	27.7%
Net Margin (TTM)	67.9%	3.4%
FCF Margin (TTM)	46.2%	7.1%
Net Income (TTM)	$197M	$209M
FCF (TTM)	$134M	$434M
EPS (TTM)	$9.03	$0.77
ROE (TTM)	20.1%	23.4%
ROA (TTM)	11.7%	1.6%
ROIC (TTM)	12.3%	2.2%
Financial Health
Cash	$1.01B	$1.13B
Debt	$1.13B	$8.55B
Net Cash/Debt	$-120M	$-7.42B
Current Ratio (TTM)	31.18x	1.95x
Quick Ratio (TTM)	30.96x	1.44x
Debt/Equity (TTM)	1.16x	8.50x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.23	1.50
52W Performance	70.8%	43.4%
YTD Performance	59.7%	90.2%
% from 52W High	-7.1%	-0.7%
% from 52W Low	72.6%	142.0%
Efficiency & Yields
Asset Turnover (TTM)	0.17x	0.47x
FCF Yield (TTM)	2.2%	12.0%
Earnings Yield (TTM)	3.2%	5.8%
Dividend Yield (TTM)	N/A	0.5%
Other
Rule of 40	101.1	4.6
EV/GP/RG	1.14	2.99
Ticker research	View LGND research	View OGN research